The Department of Health and Social Care (DHSC) has added further 28 new products to the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II
of the Drug Tariff from 1 August 2022.
PSNC said, "It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual
item' criteria and make applications to NHSBSA and DHSC, accordingly."
A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.
The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted the following price
concessions for November 2021.
Contractors can find information on the price concessions and learn about the process involved on PSNC's website.
A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHSBSA to all items submitted for payment in the same month for which a price concession is granted.
PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated November 2021 Drug Tariff price.
Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England
regarding medicine pricing issues reported by pharmacy owners (its members).
A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.
Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online
feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.
The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.
Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social
Care (DHSC).
This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating
Committee.
The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount
deduction scale will no longer apply from July 2022:
Fludrocortisone 50micrograms/5ml oral suspension (Group)
Lorazepam 1mg/5ml oral suspension (Group)
Lorazepam 500micrograms/5ml oral suspension (Group)
Zopiclone 3.75mg/5ml oral solution (Group)
Zopiclone 7.5mg/5ml oral solution (Group)
GA explore5 oral powder 12.5g sachets
HCU explore5 oral powder 12.5g sachets
MSUD explore5 oral powder 12.5g sachets
TYR explore5 oral powder 12.5g sachets
The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.
The NHS Business Services Authority (NHSBSA) has published the Drug Tariff Category M price list for July which reflects an increase in reimbursement
level of approximately £5m per quarter.
An adjustment of -£23.8m was announced, in light of the results of the margin survey (latest result up until end of December 2022), and the phasing down of the
additional £100m agreed across years 4 and 5 as part of the Community Pharmacy Contractual Framework and uplifts for underlying market prices
(between January - March 2023).
Community Pharmacy England has agreed the adjustments based on the analysis of margin delivery and on current projections for 2023/24.
It said: "The objectives are to ensure full delivery of agreed margin and smooth delivery as much as possible. As always, the impact on individual pharmacies
will vary depending on dispensing mix."
The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted final price concessions
to further items for the month of November 2021.
A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHS BSA to all items submitted for payment in the same month for which a price concession is granted.
Contractors can find information and learn about the process involved on PSNC's website.
Check pharmacy business website for price concession list november 2021.
The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted further price concessions for the month of December 2021.
A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHS BSA to all items submitted for payment in the same month for which a price concession is granted.
Contractors can find information and learn about the process involved on PSNC's website.
The Department of Health and Social Care have retrospectively granted a concessionary price for Isocarboxazid 10mg tablets for the months of May and June 2021.
While the reimbursement price had previously been £217.75, a concessionary price of £249.10 has now been granted.
The NHS Business Services Authority confirmed that payment for the difference - £31.35 for every pack of 56 claimed - will be adjusted accordingly for the mentionedtime period where contractors have submitted claims in those months. This adjustment will be paid on 31 December 2021 in the next Schedule of Payments.
The Department of Health and Social Care has updated the list of community pharmacies eligible for the Pharmacy Access Scheme (PhAS) and approved 43 cases
out of 63 applications, bringing the the total number of eligible pharmacies in England to 1,445.
Earlier this year, NHS England and NHS Improvement (NHSE&I) invited community pharmacy contractors to apply for a review if they believed there were any inaccuracies
in relation to pharmacy premises addresses or unforeseen circumstances affecting access, such as a permanent roadblock.
Submitted applications were reviewed by the relevant NHSE&I regional pharmacy contract team, and determined by the relevant pharmaceutical services regulations
committees (PSRC).
Due to the workload pressures seen over winter, the review deadline was extended, giving contractors applying for a review two full months to complete their
applications. This also pushed back the announcement of the outcome of the review, but where an application has been successful, PhAS payments will be backdated
to the start of the scheme.
The Department of Health and Social Care (DHSC) has included Tibolone 2.5mg tablets (Livial) and Prasterone 6.5mg pessaries (Intrarosa) to the list of Hormone
Replacement Therapy (HRT).
It has updated the June 2023 Drug Tariff (Part XVI) to include these additional HRT medicines for which patients will be able to purchase an HRT PPC.
"HRT is the replacement of female sex hormones oestrogen and progesterone in women to control symptoms of the menopause. Some medicines that are converted or break
down into oestrogen, progestogen or androgen hormones are prescribed for relief of menopausal symptoms. For the purposes of the HRT PPC these are included within
this definition of HRT," said DHSC.
The Pharmaceutical Services Negotiating Committee (PSNC) has challenged price concessions imposed by the Department of Health and Social Care (DHSC) on some
of the medicines.
It has raised concerns on the process for setting price concessions to senior government officials responsible for medicines supply, warning that the system is not
working in the current environment from a community pharmacy contractor perspective.
"When a new government takes over next week, this will be one of several urgent topics being raised by PSNC to new ministers, alongside the fuel price crisis,
inflationary pressures and winter pressures on pharmacy businesses," said PSNC.
The final update to August price concessions was announced yesterday taking the total concessions granted to a record 138 for August. PSNC said: "Of those, 99 were
in line with PSNC requests, but prices for 39 lines were imposed by the Department of Health and Social Care (DHSC): those impositions do not match the purchase
prices reported by contractors and the evidence of market prices which we passed on to DHSC. In particular, the final imposed prices of Apriprazole and Temazepam
tablets has generated a lot of concern amongst contractors due to the large variation between their reimbursement prices and purchase prices during the month of
August."